India’s pharmaceutical exports are projected to double to $65 billion by 2030, cementing the nation’s position as a key global supplier of affordable, high-quality medicines. Despite challenges like trade policy uncertainties and API import dependencies, India leverages innovation, improved regulatory standards, and strategic global expansion to sustain strong growth.
Overview of India’s Pharma Export Industry
- In FY 2024-25, exports reached $30.5 billion, growing at a steady 9.3% annually.
- India supplies nearly 20% of the world’s generic medicines by volume but ranks 11th globally by export value, indicating growth potential.
- Exports span over 200 countries, showcasing India’s broad international footprint.
Major Drivers Fueling Export Growth
01. Transition to Biosimilars and Complex Generics
India focuses on biosimilars, specialty medicines, and complex formulations, targeting higher-value markets.
02. Strategic Acquisitions and Expansion
Indian companies are acquiring CDMOs in regulated markets (US, Europe) to enhance market access.
03. Improved Quality & Regulatory Compliance
US FDA’s OAI inspection rates on Indian facilities dropped from 23% (2014) to 11% (2024).
04. Government Support & Policy Initiatives
Initiatives like the PLI scheme promote domestic API manufacturing and pharma infrastructure growth.
Challenges Impacting Export Growth
- Trade and Tariff Risks: Potential US tariffs up to 200% threaten pricing competitiveness.
- API Import Dependency: Over 60% APIs imported from China exposes supply chain risks.
- Rising Competition: Patent expirations (2025-2029) increase generic competition.
India’s Vision for Global Leadership
Industry reports foresee India becoming a top-five pharma exporter by 2047, aiming for $350 billion exports, driven by biosimilars, specialty generics, and increased R&D.
Benefits for Global Pharma Buyers
- Affordable, quality medicines meeting global standards (US FDA, EMA, WHO).
- Diverse product portfolio including biosimilars and complex formulations.
- Reliable supply chains backed by growing pharma infrastructure.
Conclusion
India’s pharmaceutical export sector is on a strong growth path to reach $65 billion by 2030 despite trade and supply chain challenges. This growth offers global buyers access to affordable, high-quality medicines from a dynamic market.
Jefferson Pharma Impex is proud to contribute to this expanding industry by supporting seamless pharmaceutical exports worldwide..